Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Microenvironment
Published in: Cancer Microenvironment 1/2011

Open Access 01-04-2011 | Original Paper

The Potential Role of MT and Vimentin Immunoreactivity in the Remodeling of the Microenvironment of Parotid Adenocarcinoma

Authors: Magdalena Dutsch-Wicherek, Agata Lazar, Romana Tomaszewska

Published in: Cancer Microenvironment | Issue 1/2011

Login to get access

Abstract

A tumor stimulates the remodeling of its microenvironment in order to control and accelerate its own growth and to initiate metastases. To create metastases the tumor cells must first acquire the ability to detach from the main tumor and to adhere to, invade, and degrade the adjacent extracellular matrix. The cells must then be able to enter the lumen of the vessels where they home the distant tissues and organs by forming secondary tumors. The acquisition of this phenotype is related to the phenomenon of epithelial-to-mesenchymal transition. On the molecular level, this process is typified by a change in the expression of epithelial markers and by the enhancement of the expression of mesenchymal markers like vimentin that are responsible for cell migration and invasion. Metallothioneins have been shown to help protect against apoptosis. The expression of MT by tumor cells plays an important and complex role not only because of its pro-proliferative, anti-apoptotic activity, but also because it inhibits the immune response. The aim of the present study was to evaluate the immunoreactivity of vimentin and MT in the salivary gland adenocarcinoma and its stroma in order to observe the phenomenon of stromal remodeling. The tissue samples of salivary gland adenocarcinomas and their stromas and the palatine tonsils which constituted the reference group were obtained during routine surgical procedures. The immunoreactivity of vimentin, metalothionein, CD56, CD57 antigens was evaluated by the immunohistochemistry method in 30 tissue samples of parotid adenocarcinoma. The patient’s consent was obtained in each case. A statistically significantly higher level of MT immunoreactivity was observed in the adenocarcinoma tissue slides than in either the stromal slides or the reference slides while no differences in MT immunoreactivity were detected when the stroma and reference tissue slides were compared. A statistically significantly higher vimentin immunoreactivity level was identified in the tumor microenvironment tissue slides than in the tumor tissue slides, and a statistically significantly higher level of vimentin immunoreactivity was identified in the tumor microenvironment slides than in the slides of the reference tissue, while no differences were identified between the adenocarcinoma tissue slides and the reference slides with respect to vimentin immunoreactivity. A statistically significantly higher number of CD56- and CD57-expressing cells were identified in the reference tissue slides than in either the adenocarcinoma or stromal slides. In conclusion, the stroma of salivary gland adenocarcinoma in this study has been characterized by remodeling. The remodeling is represented by the expression of both vimentin and MT and by a deficit of CD57- and CD58-expressing cell infiltration. This situation would seem to be the result of immune tolerance for the tumor developing within the tumor microenvironment. Furthermore, the presence of MT and vimentin immunoreactivity in the fibroblasts of the tumor stroma may constitute a marker of active tissue remodeling.
Literature
1.
Witz IP (2009) The tumor microenvironment: the making of a paradigm. Cancer Microenvironment 2:S9–17CrossRef
2.
Scott AM, Wiseman G, Welt S, Adjei A, Lee FT, Hopkins W, Divgi CR, Hanson LH, Mitchell P, Gansen DN, Larson SM, Ingle JN, Hoffman EW, Tanswell P, Ritter G, Cohen LS, Bette P, Arvay L, Amelsberg A, Vlock D, Rettig WJ, Old LJ (2003) A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. Clin Cancer Res 9:1639–1647PubMed
3.
Wesley UV, Albino AP, Tiwari S, Houghton AN (1999) A role for dipeptidyl peptidase IV in suppressing the malignant phenotype of melanocytic cells. J Exp Med 190:311–322PubMedCrossRef
4.
Dvorak HF (1986) Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 315:1650–1659PubMedCrossRef
5.
Lorusso G, Ruegg C (2008) The tumor microenvironment and its contribution to tumor evolution toward metastasis. Histochem Cell Biol 130:1091–1103PubMedCrossRef
6.
Acevedo VD, Gangula RD, Freeman KW, Li R, Zhang Y, Wang F, Ayala GE, Peterson LE, Ittmann M, Spencer DM (2007) Inducible FGFR-1 activation leads to irreversible prostate adenocarcinoma and an epithelial-to-mesenchymal transition. Cancer Cell 12:559–571PubMedCrossRef
7.
Hugo H, Ackland ML, Blick T, Lawrence MG, Clements JA, Williams ED, Thompson EW (2007) Epithelial–mesenchymal and mesenchymal–epithelial transitions in carcinoma progression. J Cell Physiol 213:374–383PubMedCrossRef
8.
Xu J, Wang R, Xie ZH, Odero-Marah V, Pathak S, Multani A, Chung LW, Zhau HE (2006) Prostate cancer metastasis: role of the host microenvironment in promoting epithelial to mesenchymal transition and increased bone and adrenal gland metastasis. Prostate 66:1664–1673PubMedCrossRef
9.
Grunert S, Jechlinger M, Beug H (2003) Diverse cellular and molecular mechanisms contribute to epithelial plasticity and metastasis. Nat Rev Mol Cell Biol 4:657–665PubMedCrossRef
10.
Kokkinos MI, Wafai R, Wong MK, Newgreen DF, Thompson EW, Waltham M (2007) Vimentin and epithelial-mesenchymal transition in human breast cancer—observations in vitro and in vivo. Cells Tissues Organs 185:191–203PubMedCrossRef
11.
Thiery JP (2002) Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2:442–454PubMedCrossRef
12.
Paccione RJ, Miyazaki H, Patel V, Waseem A, Gutkind JS, Zehner ZE, Yeudall WA (2008) Keratin down-regulation in vimentin-positive cancer cells is reversible by vimentin RNA interference, which inhibits growth and motility. Mol Cancer Ther 7:2894–2903PubMedCrossRef
13.
Powell DW, Mifflin RC, Valentich JD, Crowe SE, Saada JI, West AB (1999) Myofibroblasts. I. Paracrine cells important in health and disease. Am J Physiol 277:C1–C9PubMed
14.
Vered M, Allon I, Buchner A, Dayan D (2009) Stromal myofibroblasts accompany modifications in the epithelial phenotype of tongue dysplastic and malignant lesions. Cancer Microenvironment 2:49–57PubMedCrossRef
15.
De Wever O, Mareel M (2005) Role of tissue stroma in cancer cell invasion. J Pathol 200:429–447CrossRef
16.
Hayward SW, Wang Y, Cao M, Hom YK, Zhang B, Grossfeld GD, Sudilovsky D, Cunha GR (2001) (2001) Malignant transformation in a nontumorigenic human prostatic epithelial cell line. Cancer Res 61:8135–8142PubMed
17.
Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, Naeem R, Carey VJ, Richardson AL, Weinberg RA (2005) Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 121:335–348PubMedCrossRef
18.
Sugimoto H, Mundel TM, Kieran MW, Kalluri R (2006) Identification of fibroblast heterogeneity in the tumor microenvironment. Cancer Biol Ther 5:1640–1646PubMedCrossRef
19.
Klaassen CD, Liu J, Choudhuri S (1999) Metallothionein: an intracellular protein to protect against cadmium toxicity. Annu Rev Pharmacol Toxicol 39:267–294PubMedCrossRef
20.
Apostolova MD, Cherian MG (2000) Nuclear localization of metalothionein during cell proliferation and differentiation. Cell Mol Biol 46:347–356PubMed
21.
Theocharis SE, Margeli AP, Klijanienko JT, Kouraklis GP (2004) Metallothionein expression in human neoplasia. Histopathology 45:103–18PubMedCrossRef
22.
Cherian MG, Jayasurya A, Bay BH (2003) Metallothioneins in human tumors and potential roles in carcinogenesis. Mutat Res 33:201–209
23.
Fan LZ, Cherian MG (2002) Potential role of p53 on metallothionein induction in human epithelial breast cancer cells. Br J Cancer 87:1019–1026PubMedCrossRef
24.
Dutsch-Wicherek M, Popiela TJ, Klimek M, Rudnicka-Sosin L, Wicherek L, Oudinet JP, Skladzien J, Tomaszewska R (2005) Metallothionein stroma reaction in tumor adjacent healthy tissue in head and neck squamous cell carcinoma and breast adenocarcinoma. NeuroEndocrinol Lett 26:567–574PubMed
25.
Dutsch-Wicherek M, Sikora J, Tomaszewska R (2008) The possible biological role of metallothionein in apoptosis. Front Biosci 13:4029–4038PubMedCrossRef
26.
Hellquist HB (1997) Apoptosis in epithelial hyperplastic laryngeal lesions. Acta Otolaryngol Suppl 527:25–29PubMedCrossRef
27.
Sundelin K, Jadner M, Norberg-Spaak L, Davidsson A, Hellquist HB (1997) Metallothionein and Fas (CD95) are expressed in squamous cell carcinoma of the tongue. Eur J Cancer 33:1860–1864PubMedCrossRef
28.
Okada T, Iiai T, Kawachi Y, Moroda T, Takii Y, Hatakeyama K, Abo T (1995) Origin of CD57+ T cells which increase at tumour sites in patients with colorectal cancer. Clin Exp Immunol 102:159–166PubMedCrossRef
29.
Takii Y, Hashimoto S, Iiai T, Watanabe H, Hatakeyama K, Abo T (1994) Increase of the proportion of granulated CD56+ T cells in patients with malignancy. J Clin Exp Immunol 97:522–527CrossRef
30.
Satoh M, Seki S, Hashimoto W, Ogasawara K, Kobayashi T, Kumagai K, Matsuno S, Takeda K (1996) Cytotoxic gammadelta or alphabeta T cells with a natural killer cell marker, CD56, induced from human peripheral blood lymphocytes by a combination of IL-12 and IL-2. J Immunol 157:3886–3892PubMed
31.
Kuss I, Hathaway B, Ferris RL, Gooding W, Whiteside TL (2004) Decreased absolute counts of T lymphocyte subsets and their relation to disease in squamous cell carcinoma of the head and neck. Clin Cancer Res 10:3755–3762PubMedCrossRef
32.
Sallusto F, Geminat J, Lanzavecchia A (2004) Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol 22:745–763PubMedCrossRef
33.
Jayasurya A, Bay BH, Yap WM, Tan NG (2000) Correlation of metallothionein expression with apoptosis in nasopharyngeal carcinoma. Br J Cancer 82:1198–1203PubMedCrossRef
34.
Jayasurya A, Bay BH, Yap WM, Tan NG (2000) Infiltrating lymphocytes in undifferentiated nasopharyngeal cancer lack metallothionein expression. Cancer Lett 155:99–104PubMedCrossRef
35.
Popiela TJ, Rudnicka-Sosin L, Dutsch-Wicherek M, Klimek M, Basta P, Galazka K, Wicherek L (2006) The metallothionein and RCAS1 expression analysis in breast cancer and adjacent tissue regarding the immune cells presence and their activity. NeuroEndocrinol Lett 27:786–794PubMed
36.
Gao MQ, Kim BG, Kang S, Choi YP, Park H, Kang KS, Cho NH (2010) Stromal fibroblasts from the interface zone of human breast carcinomas induce an epithelial-mesenchymal transition-like state in breast cancer cells in vitro. J Cell Sci 123:3507–3514PubMedCrossRef
37.
Canpolat E, Lynes MA (2001) In vivo manipulation of endogenous metallothionein with a monoclonal antibody enhances a T-dependent humoral immune response. Toxicol Sci 62:61–70PubMed
38.
Ioachim HL (1979) The stroma reaction of tumors: An expression of immune surveillance. J Cell Biochem Suppl 57:465–475
39.
Keller SE, Ioachim HL, Pearse T, Siletti DM (1976) Decreased T-lymphocytes in patients with mammary cancer. Am J Clin Pathol 65:445–449PubMed
40.
Miescher S, Whiteside TL, Moretta L, Von Fliedner V (1987) Clonal and frequency analyses of tumor infiltrating T lymphocytes from human solid tumors. J Immunol 138:4004–4011PubMed
41.
Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL (1986) Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 136:2348–2357PubMed
42.
Trinchieri G (1995) Interleukin-12- a cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cell type 1 and cytotoxic lymphocytes. Blood 84:4008–4027
43.
Elsässer-Beile U, Kölble N, Grussenmeyer T, Schultze-Seemann W, Wetterauer U, Gallati H, Schulte Mönting J, von Kleist S (1998) Th1 and Th2 cytokine response patterns in leukocyte cultures of patients with urinary bladder, renal cell and prostate carcinomas. Tumor Biol 19:470–476CrossRef
Metadata
Title
The Potential Role of MT and Vimentin Immunoreactivity in the Remodeling of the Microenvironment of Parotid Adenocarcinoma
Authors
Magdalena Dutsch-Wicherek
Agata Lazar
Romana Tomaszewska
Publication date
01-04-2011
Publisher
Springer Netherlands
Published in
Cancer Microenvironment / Issue 1/2011
Print ISSN: 1875-2292
Electronic ISSN: 1875-2284
DOI
https://doi.org/10.1007/s12307-010-0058-z

Other articles of this Issue 1/2011

Cancer Microenvironment 1/2011 Go to the issue

Original Paper

Effect of Increased Extracellular Ca++ on Microvesicle Production and Tumor Spheroid Formation

Review Paper

Myeloid Cells in Cancer Progression: Unique Subtypes and Their Roles in Tumor Growth, Vascularity, and Host Immune Suppression

Original Paper

Differential Inductive Signaling of CD90+ Prostate Cancer-Associated Fibroblasts Compared to Normal Tissue Stromal Mesenchyme Cells

Original Paper

Proteomic Analysis of Differentially Expressed Proteins in Peripheral Cholangiocarcinoma

Brief Communication

Expression Pattern of the Pro-apoptotic Gene PAR-4 During the Morphogenesis of MCF-10A Human Mammary Epithelial Cells

Original Paper

The Involvement of RCAS1 in Creating a Suppressive Tumor Microenvironment in Patients with Salivary Gland Adenocarcinoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits